医药高增长轮动策略:年化收益率(-0.4%)
本策略精选医药生物行业中,净利润和营收均高速增长、毛利率和净利率优秀、市盈率适中,且流通市值较小的优质股票。策略通过严格的财务指标筛选,并结合小市值偏好,力求捕捉医药行业中具备高成长潜力的投资标的,并进行短期轮动持有,以期获得超额收益。
本策略精选医药生物行业中,净利润和营收均高速增长、毛利率和净利率优秀、市盈率适中,且流通市值较小的优质股票。策略通过严格的财务指标筛选,并结合小市值偏好,力求捕捉医药行业中具备高成长潜力的投资标的,并进行短期轮动持有,以期获得超额收益。
查看AI策略代码
当日收盘价 | 当日市值 | 浮动收益/浮动收益率
|
|||||
---|---|---|---|---|---|---|---|
2025-06-06 | 兴齐眼药(300573.SZ) | 55.816741176471 | 1700 | 2 | 54.23 | 92191 | -2697.46/-2.843% |
2025-06-06 | 甘李药业(603087.SH) | 49.174747368421 | 1800 | 22 | 56.33 | 101394 | 12879.45/14.551% |
2025-06-06 | 昊帆生物(301393.SZ) | 48.20617993714 | 1809 | 22 | 52.88 | 95659.92 | 8454.94/9.695% |
2025-06-06 | 大博医疗(002901.SZ) | 33.583942271174 | 2633 | 27 | 38.11 | 100343.63 | 11917.11/13.477% |
2025-06-06 | 宣泰医药(688247.SH) | 10.752347506537 | 9895 | 142 | 10.24 | 101324.8 | -5069.68/-4.765% |
2025-06-06 | 特宝生物(688278.SH) | 61.435341940248 | 1239 | 282 | 73.64 | 91239.96 | 15121.57/19.866% |
2025-06-05 | 兴齐眼药(300573.SZ) | 55.816741176471 | 1700 | 1 | 55.26 | 93942 | -946.46/-0.997% |
2025-06-05 | 甘李药业(603087.SH) | 49.174747368421 | 1800 | 21 | 56.66 | 101988 | 13473.45/15.222% |
2025-06-05 | 昊帆生物(301393.SZ) | 48.20617993714 | 1809 | 21 | 54.39 | 98391.51 | 11186.53/12.828% |
2025-06-05 | 大博医疗(002901.SZ) | 33.583942271174 | 2633 | 26 | 38.63 | 101712.79 | 13286.27/15.025% |
2025-06-05 | 宣泰医药(688247.SH) | 卖 | -300 | 10.19 | -3057 | ¥8.06 | -168.7 |
2025-06-05 | 昊帆生物(301393.SZ) | 卖 | -100 | 55.6 | -5560 | ¥10.56 | 739.38 |
2025-06-05 | 兴齐眼药(300573.SZ) | 买 | 1700 | 55.8 | 94860 | ¥28.46 | 0 |
2025-06-05 | 甘李药业(603087.SH) | 卖 | -100 | 57.16 | -5716 | ¥10.72 | 798.53 |
2025-05-30 | 大博医疗(002901.SZ) | 买 | 33 | 38.02 | -19.34 | ¥0 | 0 |
2025-05-28 | 兴齐眼药(300573.SZ) | 卖 | -1701 | 53.42 | -90867.42 | ¥118.13 | -14203.29 |
2025-05-22 | 昊帆生物(301393.SZ) | 买 | 9 | 53.5 | -12.5 | ¥0 | 0 |
2025-05-22 | 兴齐眼药(300573.SZ) | 买 | 501 | 56.15 | -20.85 | ¥0 | 0 |
2025-05-21 | 昊帆生物(301393.SZ) | 卖 | -100 | 52.52 | -5252 | ¥10.25 | 408.55 |
2025-05-14 | 宣泰医药(688247.SH) | 买 | 203 | 9.6 | 1948.8 | ¥5 | 0 |